



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

cohort study. *Lancet Rheumatol.* 2020;2:e325–31, [http://dx.doi.org/10.1016/S2665-9913\(20\)30127-2](http://dx.doi.org/10.1016/S2665-9913(20)30127-2).

Ismael Francisco Aomar-Millán^{a,*}, Juan Salvatierra^b,
José Luis Callejas-Rubio^a, Enrique Raya-Álvarez^b

^a Servicio de Medicina Interna, Hospital Clínico Universitario San Cecilio, Granada, Spain

^b Servicio de Reumatología, Hospital Clínico Universitario San Cecilio, Granada, Spain

* Corresponding author.

E-mail address: iaomarmillan@hotmail.com (I.F. Aomar-Millán).

Received 5 January 2022

<https://doi.org/10.1016/j.reumae.2022.06.001>
2173-5743/

© 2022 Published by Elsevier España, S.L.U.

Use of anakinra in the treatment of SARS-CoV-2 severe respiratory infection[☆]



Uso de anakinra en el tratamiento de la infección respiratoria grave por SARS-CoV-2

Dear Editor,

We would first like to thank Aomar-Millán et al.¹ for their response to our article in which we suggested the potential benefit of anakinra in the treatment of SARS-CoV-2 infection refractory to tocilizumab treatment.²

The “cytokine storm” secondary to SARS-CoV-2 infection leads to severe COVID-19 disease. Excessive activation of the immune system produces a picture like that of HLH.³ Increased levels of proinflammatory cytokines (IL-1, IL-6, or TNF-alpha), procoagulant factors and lymphopenia play a major role in its pathogenesis.

The use of immunosuppressants such as dexamethasone and anti-IL-6 (tocilizumab) and anti-IL-1 (anakinra) antibodies are the mainstay of treatment of the inflammatory phase of SARS-CoV-2 infection.⁴

As reported by Aomar-Millán et al., anakinra has recently been approved by the EMA for the treatment of patients with SARS-CoV-2 pneumonia who require supplemental oxygen therapy and who are at risk of progressing to severe respiratory failure as determined by a plasma concentration of soluble urokinase-type plasminogen activator receptor (suPAR) ≥ 6 ng/mL. This approval was based on the SAVE MORE study,⁵ which demonstrated a decrease in mortality and hospital stay in patients treated early with anakinra.

Interestingly, the retrospective study by Aomar-Millán et al.⁶ analysed 143 patients with SARS-CoV-2 pneumonia. Patients refractory to treatment with corticosteroids and tocilizumab were treated with anakinra at a dose of 100 mg/every 8–12 h between day 2 and 6. Administration of anakinra was associated with a reduced risk of mortality (HR: .518; 95% CI: .265 – .910; p = .0437).

The patient described in our article² received 2 doses of tocilizumab (8 mg/kg, subcutaneously) and, given the absence of respiratory and analytical improvement 48 h after tocilizumab administration, it was decided to administer anakinra (100 mg single total dose, subcutaneously). At the time the patient was admitted to hospital (April 2020), the use of anakinra in the inflammatory phase of SARS-CoV-2 pneumonia was under study. Therefore, no recommended dose had been described in the literature at that time. Currently, although there is still no consensus, higher doses and several days of continuous treatment are recommended.^{5–7} Like Aomar-Millán et al. in their response, we considered in the discussion of our article that the clinical improvement of the patient could not be explained solely by the effect

of treatment with anakinra, and that a late benefit of tocilizumab should not be ruled out.

Conflict of interests

JJC-H: Consulting or Advisory Role: MSD Oncology, Bristol-Myers Squibb, Merck Speakers' Bureau: MSD Oncology, Bristol-Myers Squibb, Merck, Roche, Janssen Oncology, AstraZeneca Travel, Accommodations, Expenses: MSD Oncology; the remaining authors have no conflict of interests to declare.

References

1. Aomar-Millán IF, Salvatierra J, Callejas-Rubio JL, Raya-Álvarez E. Anakinra, una alternativa potencial en el tratamiento de la infección respiratoria grave por SARS-CoV-2 refractaria a tocilizumab: comentario. *Reumatol Clin.* DOI: 10.1016/j.reuma.2022.01.003.
2. Figuero-Pérez L, Olivares-Hernández A, Escala-Cornejo RA, Terán-Brage E, López-Gutiérrez Á, Cruz-Hernández JJ. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab. *Reumatol Clin (Engl Ed).* 2021;17:559–61, <http://dx.doi.org/10.1016/j.reumae.2020.06.008>.
3. Wampler Muskardin TL. Anakinra for macrophage activation syndrome may hold lessons for treatment of cytokine storm in the setting of COVID-19. *ACR Open Rheumatol.* 2020;2, <http://dx.doi.org/10.1002/acr2.11140>.
4. Khan FA, Stewart I, Fabbri L, Moss S, Robinson K, Smyth AR, et al. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. *Thorax.* 2021;76(9):907–19, <http://dx.doi.org/10.1136/thoraxjnl-2020-215266>.
5. Kyriazopoulou E, Poulakou G, Milonis H, Metallidis S, Adamis G, Tsiakos K, et al. Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. *Nat Med.* 2021;27(10):1752–60.
6. Aomar-Millán IF, Salvatierra J, Torres-Parejo Ú, Faro-Míguez N, Callejas-Rubio JL, Ceballos-Torres A, et al. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study. *Intern Emerg Med.* 2021;843–52, <http://dx.doi.org/10.1007/s11739-020-02600-z>.
7. Kyriazopoulou E, Panagopoulos P, Metallidis S, Dalekos GN, Poulakou G, Gatselis N, et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. *Elife.* 2021;10:e66125, <http://dx.doi.org/10.7554/eLife.66125>.

Luis Figuero-Pérez^{a,b,*}, Alejandro Olivares-Hernández^{a,b},
Roberto A. Escala-Cornejo^c, Juan J. Cruz-Hernández^{a,b}

^a Servicio de Oncología Médica, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain

^b Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain

^c Instituto de Investigación Nacional (SOLCA) de Guayaquil, Guayaquil, Spain

* Corresponding author.

E-mail address: figuero44@gmail.com (L. Figuero-Pérez).

Received 1 February 2022

<https://doi.org/10.1016/j.reumae.2022.02.001>
2173-5743/

© 2022 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

[☆] Please cite this article as: Figuero-Pérez L, Olivares-Hernández A, Escala-Cornejo RA, Cruz-Hernández JJ. Uso de anakinra en el tratamiento de la infección respiratoria grave por SARS-CoV-2. *Reumatol Clin.* 2023;19:122.